

Relationships With Industry

Name: Paul W. Armstrong, Distinguished University Professor, University of Alberta, Founding Director, Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta **

Last updated: November 1, 2025

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company generates revenue for the University of Alberta	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Merck	2016 to present	VeriCiguaT gObal study in patients with heart failure and Reduced ejection frAction (VICTORIA)	☒	☒	☐	☐	☐	☒	☐	☐	
Boehringer Ingelheim	2017 to present / Consulting 2017-2022	STrategic Reperfusion in elderly patients Early After Myocardial Infaction (STREAM- II)	☒	☒	☐	☐	☒	☐	☐	☐	
Bayer	2018 - 2023	A Randomized Parellel-Group, Placebo Controlled, Double-Blind, Multi-Center Confirmatory Trial to Evaluate the Efficacy and Safety of the Oral sGC Stimulator on Physical Limitations in Patients with Heart Failure and Preserved Ejection Fraction (VITALITY)	☒	☒	☐	☐	☐	☒	☐	☐	
CSL Limited	2018 – 2022	A Phase III, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel- group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome (AEGIS II)	☒	☐	☐	☐	☐	☐	☐	☐	
Boehringer Ingelheim and Eli Lilly	2020 - 2023	A phase III, streamlined, multicentre, randomised, parallel group, double-blind, placebo-controlled, superiority trial to evaluate the effect of Empagliflozin on hospitalisation for heart failure and mortality in patients with acute myocardial infarction. (EMPACT-MI)	☒	☐	☐	☐	☐	☐	☐	☐	
Novo Nordisk	2024 to present	Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction (ARTEMIS)	☒	☐	☐	☐	☐	☐	☐	☐	
			☐	☐	☐	☐	☐	☐	☐	☐	
			☐	☐	☐	☐	☐	☐	☐	☐	

Monetary amounts are on an annual basis.

** Please note this document should be placed in the context that Dr. Armstrong is working 0.5 FTE at the University.